Title:
MARKER FOR DETERMINING ANTI-CANCER EFFECTS OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION PATHWAY INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/063311
Kind Code:
A1
Abstract:
The present invention relates to a marker for determining anti-cancer effects of a mitochondrial oxidative phosphorylation pathway inhibitor. Specifically, the present invention relates to use of the mitochondrial oxidative phosphorylation pathway inhibitor for preparing a composition or a formulation for preventing and/or treating tumors. The present invention has found that the mitochondrial oxidative phosphorylation pathway inhibitor has significantly excellent treatment effects on tumors having mitochondrial oxidative phosphorylation pathway up-regulation, low or no expression of an NNMT gene, high expression of a DNA methylase, high expression of UHRF1, a high methylation level of a nucleotide site of an NNMT gene and/or a high methylation level of a DNA CpG site of an NNMT gene region.
Inventors:
SHI YUFENG (CN)
MA WENJIANG (CN)
MA WENJIANG (CN)
Application Number:
PCT/CN2021/121088
Publication Date:
March 31, 2022
Filing Date:
September 27, 2021
Export Citation:
Assignee:
NANJING SHIJIANG MEDICINE TECH CO LTD (CN)
International Classes:
A61K31/365; A61K31/7042; A61K31/7056; A61K45/06; A61P35/00; G01N33/574; G01N33/577
Foreign References:
| CN106248946A | 2016-12-21 |
Other References:
LIU YU'E, SHI YUFENG: "Mitochondria as a target in cancer treatment", MEDCOMM, vol. 1, no. 2, 1 September 2020 (2020-09-01), pages 129 - 139, XP055914469, ISSN: 2688-2663, DOI: 10.1002/mco2.16
RAMSDEN DAVID B., ROSEMARY H WARING, DAVID J BARLOW, RICHARD B PARSONS: "Nicotinamide N-Methyltransferase in Health and Cancer", INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH, vol. 10, 30 June 2017 (2017-06-30), pages 1 - 19, XP055914471, DOI: 10.1177/1178646917691739
ZHANG JUN, WANG YANZHONG, LI GUILING, YU HAITAO, XIE XINYOU: "Down-Regulation of Nicotinamide N-methyltransferase Induces Apoptosis in Human Breast Cancer Cells via the Mitochondria-Mediated Pathway", PLOS ONE, vol. 9, no. 2, 18 February 2014 (2014-02-18), pages e89202 - 13019, XP055914472, DOI: 10.1371/journal.pone.0089202
VIALE, APETTAZZONI, PLYSSIOTIS, C ET AL.: "Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function", NATURE, vol. 514, 2014, pages 628 - 632, XP037437635, DOI: 10.1038/nature13611
SHI, YLIM, S.K.LIANG, Q ET AL.: "Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma", NATURE, vol. 567, 2019, pages 341 - 346, XP036735126, DOI: 10.1038/s41586-019-0993-x
NATURE MEDICINE
MOLINA, J.R.SUN, YPROTOPOPOVA, M ET AL.: "An inhibitor of oxidative phosphorylation exploits cancer vulnerability", NAT MED, vol. 24, 2018, pages 1036 - 1046, XP036542082, DOI: 10.1038/s41591-018-0052-4
"UniProt", Database accession no. P40261
"Uniprot", Database accession no. Q96T8 8
"Cancer Cell Line Encyclopedia"
See also references of EP 4218752A4
RAMSDEN DAVID B., ROSEMARY H WARING, DAVID J BARLOW, RICHARD B PARSONS: "Nicotinamide N-Methyltransferase in Health and Cancer", INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH, vol. 10, 30 June 2017 (2017-06-30), pages 1 - 19, XP055914471, DOI: 10.1177/1178646917691739
ZHANG JUN, WANG YANZHONG, LI GUILING, YU HAITAO, XIE XINYOU: "Down-Regulation of Nicotinamide N-methyltransferase Induces Apoptosis in Human Breast Cancer Cells via the Mitochondria-Mediated Pathway", PLOS ONE, vol. 9, no. 2, 18 February 2014 (2014-02-18), pages e89202 - 13019, XP055914472, DOI: 10.1371/journal.pone.0089202
VIALE, APETTAZZONI, PLYSSIOTIS, C ET AL.: "Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function", NATURE, vol. 514, 2014, pages 628 - 632, XP037437635, DOI: 10.1038/nature13611
SHI, YLIM, S.K.LIANG, Q ET AL.: "Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma", NATURE, vol. 567, 2019, pages 341 - 346, XP036735126, DOI: 10.1038/s41586-019-0993-x
NATURE MEDICINE
MOLINA, J.R.SUN, YPROTOPOPOVA, M ET AL.: "An inhibitor of oxidative phosphorylation exploits cancer vulnerability", NAT MED, vol. 24, 2018, pages 1036 - 1046, XP036542082, DOI: 10.1038/s41591-018-0052-4
"UniProt", Database accession no. P40261
"Uniprot", Database accession no. Q96T8 8
"Cancer Cell Line Encyclopedia"
See also references of EP 4218752A4
Attorney, Agent or Firm:
XU&PARTNERS, LLC. (CN)
Download PDF: